You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

nilotinib

Showing 101 - 125 of 252
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Parkinson Disease Trial in Williamsville (Lithium)

Active, not recruiting
  • Parkinson Disease
  • Williamsville, New York
    University at Buffalo
Mar 19, 2022

CML Trial in United States (nilotinib)

Completed
Has Results
  • CML
  • nilotinib
  • Birmingham, Alabama
  • +53 more
Feb 25, 2020

Chronic Myeloid Leukemia Trial in Italy (Bosutinib)

Completed
  • Chronic Myeloid Leukemia
  • Alessandria, Italy
  • +44 more
Feb 2, 2023

Myelogenous Leukemia, Chronic Trial in Worldwide (nilotinib, imatinib)

Completed
Has Results
  • Myelogenous Leukemia, Chronic
  • Los Angeles, California
  • +212 more
Oct 23, 2020

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Chronic Myeloid Leukemia - Chronic Phase Trial in Doha (Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna])

Terminated
  • Chronic Myeloid Leukemia - Chronic Phase
  • Dasatinib 100 MG [Sprycel]
  • Nilotinib 150mg oral capsule [Tasigna]
  • Doha, Qatar
    National Center for Cancer Care & Research (NCCCR)
Jan 20, 2019

Describe Real World Use of Bosutinib inSingle Centre in Scotland

Completed
  • Myeloid Leukemia
  • Glasgow, United Kingdom
    eatson West of Scotland Cancer Centre
May 3, 2022

Effect of 2nd Gen TKI in CML

Completed
  • Myeloid Leukemia, Chronic
    • Copenhagen, Denmark
    • +9 more
    Aug 14, 2019

    Conception/Pregnancy in Adult CML Treated With Tyrosine Kinase

    Recruiting
    • Chronic Myeloid Leukemia
    • Pregnancy
      • Rossano, Cosenza, Italy
      • +51 more
      Jan 4, 2022

      Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia Trial in Atlanta (Dasatinib, Imatinib Mesylate, Nilotinib)

      Terminated
      Has Results
      • Chronic Myelogenous Leukemia
      • +2 more
      • Atlanta, Georgia
        Emory University/Winship Cancer Institute
      Nov 1, 2018

      Needs of 3L+ CP-CML and With T315I-mutated CML Patients

      Completed
      • Chronic Myeloid Leukemia
      • 3L Therapy
      • T315I
      • Lyon, France
        Novartis Investigative Site
      Nov 9, 2022

      Patients Who Have Received Allo-HSCT Trial in Taipei (nilotinib)

      Completed
      • Patients Who Have Received Allo-HSCT
      • nilotinib
      • Taipei, Taiwan
        National Taiwan University Hospital
      Sep 10, 2018

      New Diagnosed Chronic Phase Chronic Myeloid Leukemia

      Recruiting
      • Validity and Safety
        • Guangzhou, Guangdong, China
          NanfangH
        Apr 9, 2022

        Colorectal Cancer, Head Neck Cancer Trial in Washington (Nilotinib + Cetuximab)

        Terminated
        • Colorectal Cancer
        • Head and Neck Cancer
        • Nilotinib + Cetuximab
        • Washington, District of Columbia
          Georgetown Lombardi Comprehensive Cancer Center
        Feb 6, 2019

        Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)

        Active, not recruiting
        • Acute Lymphoblastic Leukemia, Adult
        • +2 more
        • Ponatinib 15 MG Oral Tablet
        • Brno, Czechia
        • +6 more
        Nov 30, 2022

        Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma Trial in United States (Nilotinib)

        Completed
        Has Results
        • Mucosal Lentiginous Melanoma
        • +2 more
        • Nilotinib
        • Santa Monica, California
        • +7 more
        Oct 16, 2018

        Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL

        Active, not recruiting
        • Chronic Phase Chronic Myeloid Leukemia
          • Chicago, Illinois
          • +24 more
          May 24, 2021

          Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in

          Completed
          Has Results
          • Recurrent Acute Leukemia of Ambiguous Lineage
          • +5 more
          • Chemosensitivity Assay
          • +4 more
          • Seattle, Washington
            Fred Hutch/University of Washington Cancer Consortium
          Jun 29, 2022

          Parkinson Disease Trial in France (Radotinib HCl 50 mg, Placebo)

          Recruiting
          • Parkinson Disease
          • Radotinib HCl 50 mg
          • Placebo
          • Lille, France
          • +6 more
          Feb 13, 2022

          Metastatic Cancer Trial in Lillestrøm, Oslo (EMA-approved ATI based targeted therapy)

          Completed
          • Metastatic Cancer
          • EMA-approved ATI based targeted therapy
          • Lillestrøm, Norway
          • +1 more
          Mar 12, 2019

          IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)

          Withdrawn
          • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
          • IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)
          • Seongnam, Gyong-gi Province, Korea, Republic of
          • +11 more
          Jul 5, 2019

          Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome Trial

          Completed
          Has Results
          • Chronic Myelogenous Leukemia
          • +3 more
          • Nilotinib
          • Duarte, California
          • +100 more
          Jun 8, 2021

          Cancer Target Therapy Efficacy

          Active, not recruiting
          • Cancer
          • RNA sequencing
          • +5 more
          • Walnut, California
          • +6 more
          Sep 13, 2021

          Leukemia Trial in Worldwide (drug, genetic, other)

          Completed
          • Leukemia
          • nilotinib
          • +4 more
          • San Antonio, Texas
          • +5 more
          Jul 23, 2018

          Mild Cognitive Impairment, Dementia Trial in Santa Monica (bosutinib)

          Enrolling by invitation
          • Mild Cognitive Impairment
          • Dementia
          • Santa Monica, California
            Neurological Associates of West LA
          Feb 25, 2021